rheumatology
Psoriatic arthritis

Early but modest benefit from apremilast in PsA

Apremilast probably has an early but limited role to play in patients with psoriatic arthritis largely due to its safety and ease of use. The PALACE 4 study of apremilast (20 or 30mg) versus placebo found the oral phosphodiesterase 4 inhibitor achieved response rates of about 30% in DMARD- and biologic-naive patients. At week 16, ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic